ADSB-FUB-187
Synthetic cannabinoid
- CA: Schedule II
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
- 7-chloro-N-[(2S)-1-[2-(cyclopropylsulfonylamino)ethylamino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
- 1185283-97-9
Y
- 44186812
- 65322246
- L6K9PBL5EO
- Interactive image
- CC(C)(C)[C@@H](C(=O)NCCNS(=O)(=O)C1CC1)NC(=O)C2=NN(C3=C2C=CC=C3Cl)CC4=CC=C(C=C4)F
InChI
- InChI=1S/C26H31ClFN5O4S/c1-26(2,3)23(25(35)29-13-14-30-38(36,37)18-11-12-18)31-24(34)21-19-5-4-6-20(27)22(19)33(32-21)15-16-7-9-17(28)10-8-16/h4-10,18,23,30H,11-15H2,1-3H3,(H,29,35)(H,31,34)/t23-/m1/s1
- Key:UANJTRHQSBHCID-HSZRJFAPSA-N
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM.[1] It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[2]
Legality
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.[3]
See also
References
- ^ Banister SD, Connor M (2018). "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 191–226. doi:10.1007/164_2018_144. ISBN 978-3-030-10560-0. PMID 30105473.
- ^ WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Landis S, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KW, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc..
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" [Cannabinoids are proposed to be classified as hazardous to health] (in Swedish). Folkhälsomyndigheten (The Swedish Public Health Agency). Archived from the original on 25 March 2015. Retrieved 8 July 2015.
- v
- t
- e
(comparison)
| Cannabibutols |
|
|---|---|
| Cannabichromenes | |
| Cannabicyclols |
|
| Cannabidiols | |
| Cannabielsoins |
|
| Cannabigerols | |
| Cannabiphorols |
|
| Cannabinols | |
| Cannabitriols |
|
| Cannabivarins |
|
| Delta-8-tetrahydrocannabinols |
|
| Delta-9-tetrahydrocannabinols | |
| Delta-10-Tetrahydrocannabinols | |
| Miscellaneous cannabinoids |
|
| Active metabolites |
- Arachidonoyl ethanolamide (AEA; anandamide)
- 2-Arachidonoylglycerol (2-AG)
- 2-Arachidonyl glyceryl ether (2-AGE; noladin ether)
- 2-Oleoylglycerol (2-OG)
- N-Arachidonoyl dopamine (NADA)
- N-Arachidonylglycine (NAGly)
- 2-Arachidonoyl lysophosphatidylinositol (2-ALPI)
- N-Arachidonoyl serotonin (AA-5-HT)
- Docosatetraenoylethanolamide (DEA)
- Lysophosphatidylinositol (LPI)
- Oleamide
- Oleoylethanolamide (OEA)
- Palmitoylethanolamide (PEA)
- RVD-Hpα
- Stearoylethanolamide (SEA)
- O-Arachidonoyl ethanolamine (O-AEA; virodhamine)
cannabinoid
receptor
agonists /
neocannabinoids
| Classical cannabinoids (dibenzopyrans) |
|
|---|---|
| Non-classical cannabinoids |
|
| Adamantoylindoles |
|
| Benzimidazoles | |
| Benzoylindoles |
|
| Cyclohexylphenols | |
| Eicosanoids |
|
| Hydrocarbons | |
| Indazole carboxamides | |
| Indazole-3- carboxamides |
|
| Indole-3-carboxamides |
|
| Indole-3-carboxylates | |
| Naphthoylindazoles | |
| Naphthoylindoles |
|
| Naphthoylpyrroles | |
| Naphthylmethylindenes | |
| Naphthylmethylindoles | |
| Phenylacetylindoles | |
| Pyrazolecarboxamides |
|
| Pyrrolobenzoxazines | |
| Quinolinyl esters | |
| Tetramethylcyclo- propanoylindazoles | |
| Tetramethylcyclo- propanoylindoles | |
| Tetramethylcyclo- propylindoles | |
| Others |
|
enhancers
(inactivation inhibitors)
- 4-Nonylphenylboronic acid
- AM-404
- Arachidonoyl serotonin
- Arvanil
- BIA 10-2474
- Biochanin A
- CAY-10401
- CAY-10429
- Genistein
- Guineesine
- IDFP
- JNJ 1661010
- JNJ-42165279
- JZL184
- JZL195
- Kaempferol
- LY-2183240
- MK-4409
- O-1624
- O-2093
- Oleoylethanolamide (OEA)
- Olvanil
- Palmitoylethanolamide (PEA)
- PF-04457845
- PF-622
- PF-750
- PF-3845
- PHOP
- URB-447
- URB-597
- URB-602
- URB-754
- VDM-11
(antagonists/inverse
agonists/antibodies)
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- BML-190
- Brizantin (Бризантин)
- CAY-10508
- CB-25
- CB-52
- CB-86
- Dietressa (Диетресса)
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PipISB
- PSB-SB-487
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TM-38837
- VCHSR
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
